Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Vaccine. 2010 Dec 6;28(52):8345-51. doi: 10.1016/j.vaccine.2009.04.082. Epub 2009 Jul 15.
Persistent infection with high-risk human papillomaviruses (HPVs) is the greatest risk factor for the development of HPV-associated cancers. In this study rabbits bearing persistent and potentially malignant papillomas were used to test the efficacy of vaccination with a recombinant DNA and/or vesicular stomatitis virus (VSV) targeting the cottontail rabbit papillomavirus (CRPV) E6 protein. Immune responses were primed with either vector and boosted twice with the homologous or heterologous E6 vector. Over the course of 18 weeks, E6 vaccination reduced papilloma volumes to one third the volume in the controls, and the rabbits boosted with an heterologous vector tended to mount stronger responses. Small and medium-sized papillomas responded significantly but only slightly better than large papillomas. Finally the initial papilloma burden per rabbit, ranging from <100 mm(3) to >1000 mm(3), was not prognostic of antitumor efficacy. In summary both E6 vaccines elicited significant therapeutic immunity, and their sequential use tended to be advantageous.
持续性感染高危型人乳头瘤病毒（HPV）是 HPV 相关癌症发展的最大风险因素。在这项研究中，我们使用持续性和潜在恶性乳头瘤病兔来测试针对棉尾兔乳头瘤病毒（CRPV）E6 蛋白的重组 DNA 和/或水疱性口炎病毒（VSV）疫苗的疗效。免疫反应首先用载体引发，然后用同源或异源 E6 载体进行两次加强。在 18 周的时间里，E6 疫苗接种将肿瘤体积减少到对照组的三分之一，并且用异源载体加强的兔子往往会产生更强的反应。小和中等大小的乳头瘤瘤对治疗的反应显著，但只比大乳头瘤瘤稍好。最后，每只兔子的初始乳头瘤负担，从<100mm(3)到>1000mm(3)，与抗肿瘤疗效无关。总之，两种 E6 疫苗都引起了显著的治疗性免疫，它们的序贯使用往往是有利的。
